Investing News NetworkMay 28, 2024Ovarian cancer diagnostics company, Cleo Diagnostics Limited (ASX:COV) (CLEO, or the Company) is pleased to announce the publication of a milestone article on its blood test for the accurate and early detection of ovarian cancer. HighlightsA benchmarking study comparing CLEO’s ovarian cancer blood test against ultrasound has been published in scientific journal “Cancers”The study confirmed that CLEO’s initial test for the surgical triage market:Significantly outperforms current clinical workflows that use CA125 and ultrasound to predict malignancy;Correctly detected 90% of early-stage cancers compared to only 50% using standard workflows; andCan be easily adopted for use into clinical practice.The superior performance of CLEO’s test now compared to all current routine clinical tools shows the significant global potential for the test in clinical decision making prior to surgical intervention.

投资新闻网2024年5月28日卵巢癌诊断公司Cleo diagnostics Limited（ASX:COV）（Cleo，或该公司）很高兴宣布发表一篇关于其血液检测的里程碑文章，以准确和早期发现卵巢癌。HighlightsA比较CLEO卵巢癌血液检查与超声波检查的基准研究已发表在科学期刊“癌症”上。该研究证实，CLEO对外科分诊市场的初步测试：明显优于目前使用CA125和超声波预测恶性肿瘤的临床工作流程；正确检测到90%的早期癌症，而使用标准工作流程仅检测到50%；并且可以很容易地用于临床实践。与目前所有常规临床工具相比，CLEO测试的优越性能表明，在手术干预之前，该测试在临床决策中具有巨大的全球潜力。

The article, entitled ‘Utility of a Multi-Marker Panel with Ultrasound for Enhanced Classification of Adnexal Mass’ was published in peer reviewed medical journal, “Cancers”.A copy of the publication is available here: https://www.mdpi.com/2072-6694/16/11/2048CLEO’s Blood Test Far Superior to Current Standard of Care The benchmarking study compared CLEO’s ovarian cancer blood test against the current standard clinical workflows that use CA125 and ultrasound to predict malignancy.

这篇题为“超声多标记面板在附件肿块增强分类中的应用”的文章发表在同行评审的医学期刊“癌症”上。该出版物的副本可在此处获得：https://www.mdpi.com/2072-6694/16/11/2048CLEO的血液检测远优于当前的护理标准该基准研究将CLEO的卵巢癌血液检测与当前使用CA125和超声波预测恶性肿瘤的标准临床工作流程进行了比较。

The outcomes of the study build on previous results (see ASX Announcements 6 November 2023, and 25 March 2024) which clearly demonstrate that CLEO’s ovarian cancer blood test is far superior to all routine clinical tools used by doctors to ‘predict’ the diagnosis of an adnexal mass prior to surgery.

该研究的结果建立在先前的结果基础上（参见ASX公告2023年11月6日和2024年3月25日），这些结果清楚地表明，CLEO的卵巢癌血液检测远远优于医生在手术前“预测”附件肿块诊断的所有常规临床工具。

Importantly, CLEO’s test correctly detected 90% of early-stage cancers co.

重要的是，CLEO的测试正确地检测到90%的早期癌症。